A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

Active:	Yes
Cancer Type:	Brain & Spinal Cord Tumor Melanoma Solid Tumor Thyroid Cancer	NCT ID:	NCT05503797
Trial Phases:	Phase II	Protocol IDs:	F8394-201 (primary) NCI-2023-03273 2022-000627-20
Eligibility:	10 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Fore Biotherapeutics
NCI Full Details:	http://clinicaltrials.gov/show/NCT05503797

Summary

The objective of this Master Protocol is to evaluate the efficacy and safety of
plixorafenib in participants with locally advanced or metastatic solid tumors, or
recurrent or progressive primary central nervous system (CNS) tumors harboring BRAF
fusions, or in participants with rare BRAF V600-mutated solid tumors, melanoma, thyroid,
or recurrent primary CNS tumors.

Treatment Sites in Georgia

Northside Hospital Cancer Institute
1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-303-3355
www.northside.com

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.